Stem Cells 2017 May 22. Epub 2017 May 22.
Max Delbrueck Center for Molecular Medicine (MDC), Mitochondrial and Cell Fate Reprogramming, Department of Neuroproteomics, Berlin, Germany.
High attrition rates and loss of capital plague the drug discovery process. This is particularly evident for mitochondrial disease that typically involves neurological manifestations and is caused by nuclear or mitochondrial DNA defects. This group of heterogeneous disorders is difficult to target because of the variability of the symptoms among individual patients and the lack of viable modeling systems. Read More